Bristol-myers Squibb Compnay

Pharmacopeia Inc.

Bristol Meyers Squibb Company

Alaric J Dyckman

Dharmpal S Dodd

Sreekantha Ratna Kumar

Christopher P Mussari

Katerina Leftheris

Laxman Pasunoori

Stephen T Wrobleski

John L Gilmore

Trevor C Sherwood

Subramanya Hegde

T G Murali Dhar

Shoshana L Posy

Brian K Whiteley

Tasir Shamsul Haque

Jagabandhu Das

Chunjian Liu

Hai-Yun Xiao

John E Macor

John T Hynes

Ramesh Kumar Sistla

David Marcoux

Anupama Kandhi Ramachandra Reddy

Srinivasan Kunchithapatham Duraisamy

Michael G Yang

Louis John Lombardo

Zili Xiao

Rushith Kumar Anumula

William John Pitts

Robert V Moquin

Pitani Veera Venkata Srinivas

Scott Hunter Watterson

Steven H Spergel

David R Tortolani

Durga Buchi Raju Barre

John J Baldwin

Michael A Poss

Shawn David Erickson

James M Lin

Wei Li

Jollie D Godfrey, Jr

Bang-Chi Chen

Rulin Zhao

Edward McDonald

Jeffrey John Letourneau

Shuqun Lin

Ian Henderson

John Anthony Grosso

Axel Metzger

Wendel William Doubleday

Yvonne Class Shimshock

Zhongping Shi

Kevin Joseph Moriarty

Ling Li

Gulzar Ahmed

Zahid Hussain

James Wen

Junjun Wu

Makonen Belema

Soo Sung Ko

Robert J Cherney

Yuping Qiu

Arthur M P Doweyko

Ryan M Moslin

Patrice Gill

Marta Dabros

F Christopher Zusi

Charles Malcolm Langevine

Michael E Mertzman

James Kempson

Louis J Lombardo

Tg Murali Dhar

Daniel Richard Roberts

T G Dhar

Claude Quesnelle

Eric J Chan

Vikram Bhogadi

Tasir Shamsul Hague

Anupame Kandhi Ramachandra Reddy

Edward Mcdonald

Charles M Langevine

TG Murali Dhar

Subramaya Hegde

Anupama Ramachandra

Srinivasan Kunchithaptham Duraisamy

Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein X, Y, A, G, R, and Rare defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Substituted bicyclic heteroaryl compounds

Disclosed are compounds of Formula (I) or salts thereof, wherein R, R, R, R, and Rare defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Substituted carbazole compounds

Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R, R, R, R, and Rare as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha

Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Substituted benzimidazolone compounds

Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein X is CRor N; and G, A, R; and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Substituted indole and indazole compounds

Disclosed are compounds of Formula (I) (I) N-oxides, or salts thereof, wherein R, G, A, R, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Substituted indole ether compounds

Disclosed are compounds of Formula (I) Formula (I) N-oxides, or salts thereof, wherein G, G, L, R, R, R, R, n, m, x, and y are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Substituted indole dimer compounds

Disclosed are compounds of Formula (I) or a salt thereof, wherein R, R, R, R, R, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

[1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds

Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein A, G, R, R, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

6-azaindole compounds

Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R, R, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Substituted indole compounds useful as TLR inhibitors

4-azaindole compounds

Disclosed are compounds of Formula (I) or salts thereof, wherein Ring Het, R, R, R, R, R, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Substituted indole compounds

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein Ris &#x2014;OH or &#x2014;OP(O)(OH), and X, X, X, R, R, R, R, and Rare defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Substituted bicyclic compounds

Growing community of inventors

Lawrenceville, NJ, United States of America

Alaric J Dyckman